

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **VOLUNTARY ANNOUNCEMENT**

### **ASCLETIS ANNOUNCES POSITIVE PRECLINICAL DATA FOR THE MOST COMPREHENSIVE ONCE-WEEKLY ORAL PEPTIDE PIPELINE FOR THE TREATMENT OF OBESITY**

- *Ascletis’ industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.*
- *ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug candidate of Ascletis’ once-weekly oral peptide pipeline and its Phase I study has started in the U.S.*
- *ASC36o demonstrated a half-life of approximately 7 days and oral bioavailability of 6% to 8% in non-human primates (NHPs), supporting once-weekly oral administration.*
- *Using ASC36o as a cornerstone, Ascletis has developed two first-in-class once-weekly oral peptide fixed-dose combinations (FDCs), ASC36\_37o FDC (amylin/GLP-1/GIP/GCG) and ASC36\_35o FDC (amylin/GLP-1/GIP).*
- *Ascletis’ once-weekly oral peptide pipeline was developed by its Peptide Oral Transport ENhancement Technology (POTENT) that increased oral bioavailability through both gastric and intestinal absorption and reduced within-subject and between-subject variability.*

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announced positive preclinical data demonstrating the long half-lives and superior bioavailability of its industry-leading once-weekly oral peptide pipeline.

## The industry's most comprehensive once-weekly oral peptide pipeline

The foundation of Ascletis' industry-leading once-weekly oral peptide pipeline (Table 1) for the treatment of obesity and other metabolic diseases is a first-in-class once-weekly oral amylin receptor peptide agonist ASC36o (tablet) which is currently in a Phase I study in the U.S. The topline human pharmacokinetic (PK) data of ASC36o are expected by the end of 2026. At steady state in non-human primates (NHPs), ASC36o tablets reached a half-life of up to 167 hours (approximately 7 days) and oral bioavailability of 6% to 8%. In a head-to-head diet-induced obesity (DIO) rat study comparing ASC36 to eloralintide and petrelintide, ASC36 demonstrated 32% and 91%, respectively, greater body weight reduction.

**Table 1. Ascletis' once-weekly oral peptide pipeline covers all four validated targets, alone and in combination:**

| Program       | Amylin R | GLP-1R | GIPR | GCGR | Status                             |
|---------------|----------|--------|------|------|------------------------------------|
| ASC36o        | ✓        |        |      |      | U.S. Phase I                       |
| ASC36_37o FDC | ✓        | ✓      | ✓    | ✓    | FDA IND submission expected 4Q2026 |
| ASC36_35o FDC | ✓        | ✓      | ✓    |      | FDA IND submission expected 4Q2026 |
| ASC37o        |          | ✓      | ✓    | ✓    | FDA IND submission expected 4Q2026 |
| ASC35o        |          | ✓      | ✓    |      | FDA IND submission expected 4Q2026 |

*Notes:*

FDC: fixed-dose combination; R: receptor; GLP-1R: glucagon-like peptide 1 receptor; GIPR: gastric inhibitory polypeptide receptor; GCGR: glucagon receptor; FDA: the U.S. Food and Drug Administration; IND: Investigational New Drug.

### First-in-class once-weekly oral fixed-dose combination (FDC) peptides

Ascletis' two FDC oral peptides combine its amylin receptor agonist with incretin agonists in a single once-weekly pill:

- **ASC36\_37o FDC** (tablet), a once-weekly oral **quadruple** peptide agonist (amylin receptor + GLP-1R/GIPR/GCGR)
- **ASC36\_35o FDC** (tablet), a once-weekly oral **triple** peptide agonist (amylin receptor + GLP-1R/GIPR)

In NHPs, combining the peptides extended the half-lives beyond that observed with the single agent. The half-life of ASC36o increased from approximately 7 days as monotherapy to approximately 8.8 days in an FDC of ASC36\_35o, and approximately 8.3 days in an FDC of ASC36\_37o. ASC36o oral bioavailability also rose, from 6% to 8% alone to ≥10% in both FDCs (Table 2).

Furthermore, the Company's pipeline includes a once-weekly oral GLP-1/GIP/GCG triple peptide agonist, ASC37o, and a once-weekly oral GLP-1/GIP dual peptide agonist, ASC35o (Table 1). This pipeline gives Ascletis a unique competitive position to significantly expand the population that can be treated with oral agents.

## Industry-leading oral bioavailability across our once-weekly oral peptide pipeline

All five of Ascletis' once-weekly oral peptides/fixed-dose combinations utilize Ascletis proprietary Peptide Oral Transport Enhancement Technology (POTENT). In both dogs and NHPs, POTENT increases oral bioavailability through absorption in both the stomach and the intestines. POTENT also significantly reduces within-subject and between-subject variability after oral dosing. This technology allowed for oral bioavailability of Ascletis' once-weekly oral peptides of up to > 10% at the steady state, with half-lives up to approximately 8.8 days in NHPs (Table 2). These high rates of oral bioavailability combined with extremely long half-lives allows for commercially viable once-weekly dosing of its oral peptides.

**Table 2. Half-life and bioavailability of oral peptide pipeline at steady state in NHPs**

| Tablet        | Half-life                                                                              | Oral bioavailability        |
|---------------|----------------------------------------------------------------------------------------|-----------------------------|
| ASC36o        | Up to 167 hours (approx. 7 days)                                                       | 6% to 8%                    |
| ASC36_37o FDC | ASC36: up to 200 hours (approx. 8.3 days)<br>ASC37: up to 96 hours (4 days)            | ASC36: >10%<br>ASC37: ≥9.1% |
| ASC36_35o FDC | ASC36: up to 212 hours (approx. 8.8 days)<br>ASC35: up to 158 hours (approx. 6.6 days) | ASC36: ≥10%<br>ASC35: ≥9.3% |
| ASC37o        | Up to 79 hours (approx. 3.3 days)                                                      | 3.5% to 7.9%                |
| ASC35o        | Up to 83 hours (approx. 3.5 days)                                                      | Similar to ASC37o           |

*Notes:*

NHPs: non-human primates; FDC: fixed-dose combination; approx.: approximately.

“With the start of our U.S. Phase I study, our once-weekly oral peptide platform has crossed another milestone.” said Jinzi Jason Wu, Ph.D., Founder, Chairman of the Board and chief executive officer of Ascletis, “Our two FDC tablets are, to our knowledge, the first once-weekly oral fixed-dose combinations of peptides. Together with ASC37o and ASC35o, they give Ascletis what we believe is the most comprehensive once-weekly oral peptide pipeline in the industry, covering all four validated targets: amylin, GLP-1, GIP and GCG receptors. Our POTENT platform increased absorption in both the stomach and the intestine and reduced variability within and between animal subjects, and our unique combinations improved both even further. We look forward to the topline human PK data of ASC36o (tablet) and the submission of Investigational New Drug applications (INDs) for our four additional once-weekly oral peptide programs by year-end.”

### About POTENT

Peptide Oral Transport ENhancement Technology (POTENT) is Ascletis' proprietary oral peptide delivery platform. It is designed to increase oral bioavailability and reduce within-subject and between-subject PK variability, so that peptides can be dosed orally once weekly. In NHPs and dogs, POTENT increased peptide absorption at both gastric and intestinal sites.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC36o, ASC36\_37o FDC, ASC36\_35o FDC, ASC37o and/or ASC35o successfully.

By order of the Board  
**Ascleitis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hong Kong  
October 20, 2026

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*